April 23, 2025 02:38 PM EDTUpdated 04:29 PM

Top pharma companies increased lobbying spend in first quarter of 2025

Zachary Brennan

Senior Editor

Pfizer, Novartis, Amgen, Eli Lilly and Johnson & Johnson were the top congressional lobbying spenders among the major biopharma companies, as the industry faces a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Top pharma companies increased lobbying spend in first quarter of 2025

Zachary Brennan

Senior Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

Pharma's wins and losses in Trump's sprawling executive order on drug prices

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Top phar­ma com­pa­nies in­creased lob­by­ing spend in first quar­ter of 2025

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Top pharma companies increased lobbying spend in first quarter of 2025